Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Vasculitis
•
Tocilizumab
•
GCA
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
Related Questions
What is your approach to patients with GCA who have difficulty with prednisone weaning (20mg) despite use of tocilizumab?
How would you approach management of nodular scleritis in the setting of suspected GCA?
How would you interpret a temporal artery biopsy demonstrating focal chronic inflammation in the adventitia associated with small adventitial vessels and nerves without inflammation of the intima and media and without giant cells?
Do you utilize temporal artery ultrasound in your practice?
How would you approach evaluation of a patient with multiple vertebral artery pseudoaneurysms and history of dissection, but without other areas of pseudoaneurysms?
How do you approach the workup of clinically diagnosed cutaneous vasculitis in healthy young individuals without systemic symptoms?
How would you manage a patient with ANCA associated vasculitis who has recurrent flare including pulmonary hemorrhage, persistent MPO antibody positivity while on maintenance rituximab and avacopan regimen even after induction rituximab therapy?
How would you approach the work up of a patient with nasal septal perforation, a negative infectious workup, and negative ANCA titers?
Is a persistently elevated IgE level clinically relevant in a patient who has otherwise good control of EGPA and completely suppressed eosinophils on mepolizumab?
When do you consider Mesna for patients taking oral cyclophosphamide?
